KPMG, a New York City-based advisory firm, conducted the survey in February. The company polled 100 IT and information security officers from large U.S.-based drug and device companies about their cybersecurity concerns. About half of the executives were solely responsible for cybersecurity at their companies.
Here are four survey findings.
- Eighty-two percent of executives cited financial information as the most targeted asset in cyberattacks, followed by intellectual property (79 percent) and clinical research (49 percent).
- A majority of respondents (53 percent) said they were more concerned about government-sponsored hackers working for other countries than individual hackers.
- The top two cybersecurity priorities medical device executives named were better technology (38 percent) and an overarching strategy for data collection and protection (28 percent).
- Drug company executives listed stronger processes (24 percent) as the largest cybersecurity need, followed by more funding and better technology (22 percent) and more staffing (9 percent).
More articles on supply chain:
Celgene’s leukemia drug earns FDA approval
4 thoughts on modernizing the supply chain with a Cardinal Health leader
FDA to pre-certify digital health companies in pilot program
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
